ACUR has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
ACUR has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Acura Pharmaceuticals's enterprise value is $0.32 Mil. Acura Pharmaceuticals's EBITDA for the trailing twelve months (TTM) ended in Dec. 2021 was $-0.59 Mil. Therefore, Acura Pharmaceuticals's EV-to-EBITDA for today is -0.54.
The historical rank and industry rank for Acura Pharmaceuticals's EV-to-EBITDA or its related term are showing as below:
During the past 13 years, the highest EV-to-EBITDA of Acura Pharmaceuticals was 4.75. The lowest was -5.83. And the median was 0.00.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
As of today (2024-04-18), Acura Pharmaceuticals's stock price is $0.0028. Acura Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2021 was $-0.023. Therefore, Acura Pharmaceuticals's PE Ratio for today is At Loss.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.
The historical data trend for Acura Pharmaceuticals's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Acura Pharmaceuticals's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Drug Manufacturers industry and Healthcare sector, Acura Pharmaceuticals's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Acura Pharmaceuticals's EV-to-EBITDA falls into.
Acura Pharmaceuticals's EV-to-EBITDA for today is calculated as:
EV-to-EBITDA | = | Enterprise Value (Today) | / | EBITDA (TTM) |
= | 0.320 | / | -0.589 | |
= | -0.54 |
Acura Pharmaceuticals's current Enterprise Value is $0.32 Mil.
Acura Pharmaceuticals's EBITDA for the trailing twelve months (TTM) ended in Dec. 2021 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.59 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Acura Pharmaceuticals (OTCPK:ACUR) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Acura Pharmaceuticals's PE Ratio for today is calculated as:
PE Ratio | = | Share Price (Today) | / | Earnings per Share (Diluted) (TTM) |
= | 0.0028 | / | -0.023 | |
= | At Loss |
Acura Pharmaceuticals's share price for today is $0.0028.
Acura Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2021 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.023.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.
Please read Which price ratio outperforms the enterprise multiple?
Thank you for viewing the detailed overview of Acura Pharmaceuticals's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
Bruce F Wesson | director | 1827 PACIFIC ST BROOKLYN NY 11233 |
William G Skelly | director | C/O ACURA PHARMACEUTICALS, INC. 616 N. NORTH COURT, SUITE 120 PALATINE IL 60067 |
George K Ross | director | 1350 TREAT BLVD SUITE 250 WALNUT CREEK CA 94596 |
James F Emigh | officer: VP, Corporate Development | |
Immanuel Thangaraj | director | 10001 WOODLOCH FOREST DRIVE SUITE 175 THE WOODLANDS TX 77380 |
Robert A Seiser | officer: VP, Treasurer & Controller | C/O ACURA PHARMACEUTICALS, INC. 616 N. NORTH COURT SUITE 120 PALATINE IL 60067 |
Robert B Jones | officer: President & CEO | C/O ACURA PHARMACEUTICALS, INC. 616 N NORTH COURT PALATINE IL 60067 |
Albert W Brzeczko | officer: VP Pharmaceutical Sciences APT | C/O ACURA PHARMACEUTICALS, INC. 660 N. NORTH COURT PALATINE IL 60067 |
Peter A Clemens | officer: Senior VP & CFO | C/O HALSEY DRUG CO INC 1827 PACIFIC STREET BROOKLYN NY 11233 |
Abuse Deterrent Pharma, Llc | 10 percent owner | 333 EAST MAIN STREET SUITE 200 LOUISVILLE KY 40202 |
Claudius Llc | 10 percent owner | C/O GALEN ASSOCIATES 610 FIFTH AVENUE 5TH FLOOR NEW YORK NY 10020 |
John Schutte | 10 percent owner | 9707 SHELBYVILLE ROAD, LOUISVILLE KY 40233 |
Galen Partners Iii L P | 10 percent owner | 610 FIFTH AVE 5TH FL NEW YORK NY 10020 |
Galen Management, Llc | 10 percent owner | 680 WASHINGTON BLVD, STAMFORD CT 06901 |
Galen Employee Fund Iii Lp | 10 percent owner | 610 FIFTH AVENUE 5TH FLOOR NEW YORK NY 10020 |
From GuruFocus
By Marketwired Marketwired • 10-01-2019
By Marketwired Marketwired • 07-03-2019
By gurufocus 10qk • 10-26-2009
By Marketwired Marketwired • 10-29-2020
By Marketwired Marketwired • 02-28-2020
By gurufocus • 05-01-2009
By Marketwired Marketwired • 05-17-2021
By Marketwired Marketwired • 03-31-2020
By gurufocus 10qk • 11-02-2010
By gurufocus • 07-31-2009
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.